All In Biotech

NDA 214628 · Long Grove Pharms

Norepinephrine Bitartrate In 0.9% Sodium Chloride

Norepinephrine Bitartrate · Intravenous

Last checked: Nov 19, 2026Latest source record: Dec 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Oct 6, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

2 Phase 3, 2 recruiting

FAERS reports

13,464

12,974 serious, 4,381 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 30, 2026.

Norepinephrine in Sodium Chloride Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension. Norepinephrine in Sodium Chloride Injection is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states. ( 1 )

Mechanism: Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 6, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterReview
3 products under this application
  • NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · NOREPINEPHRINE BITARTRATE EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · NOREPINEPHRINE BITARTRATE EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · NOREPINEPHRINE BITARTRATE EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Norepinephrine Bitartrate" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,961
  • off label use1,391
  • hypotension1,343
  • acute kidney injury929
  • multiple organ dysfunction syndrome891
  • condition aggravated868
  • sepsis740
  • toxicity to various agents737
  • cardiac arrest684
  • cardiogenic shock683
  • septic shock591
  • respiratory failure514

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200464
200571
200690
200791
200879
200990
2010120
2011233
2012161
2013109
2014187
2015244
2016358
2017462
2018491
2019575
20201,384
20211,508
20221,422
20231,590
20241,549
20251,573
20261,012

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Long Grove Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.